Last updated: February 19, 2026
IRESSA (gefitinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily for the treatment of non-small cell lung cancer (NSCLC). Its market performance is directly tied to the evolution of NSCLC treatment paradigms, particularly the increasing stratification of therapies based on genetic biomarkers. Gefitinib was one of the first targeted therapies approved for NSCLC, marking a significant shift from traditional chemotherapy.
What is IRESSA’s Approved Indication and Mechanism of Action?
IRESSA is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have specific EGFR mutations (exon 19 deletions or exon 21 L858R substitutions). It functions by inhibiting the intracellular tyrosine kinase domain of EGFR. This inhibition blocks downstream signaling pathways that are crucial for tumor cell proliferation, survival, and metastasis. The efficacy of gefitinib is significantly higher in patients with tumors harboring these sensitizing EGFR mutations compared to those without.
The development of gefitinib was a precursor to a wave of targeted therapies in oncology. Its initial approval by the U.S. Food and Drug Administration (FDA) in May 2003, under the brand name Iressa, was based on overall response rate and progression-free survival in a broad NSCLC population. However, subsequent clinical trials, notably the Iressa Pan-Asia Study (IPAS), demonstrated its superior efficacy in patients with EGFR mutations, leading to revised labeling and treatment guidelines.
How has IRESSA’s Market Share Evolved with the Advent of New EGFR Inhibitors?
The market landscape for EGFR inhibitors in NSCLC has become increasingly competitive since IRESSA's introduction. The development of second and third-generation EGFR TKIs has led to a dynamic shift in treatment selection and market share.
- First-Generation (Gefitinib, Erlotinib): These agents target common EGFR mutations but face challenges with resistance mechanisms, primarily the T790M mutation, which emerges after initial treatment.
- Second-Generation (Afatinib, Dacomitinib): These irreversibly bind to EGFR and can target a broader range of mutations, including some resistance mutations, but are associated with higher rates of toxicity.
- Third-Generation (Osimertinib): Osimertinib is a highly selective, irreversible EGFR TKI that targets both sensitizing mutations and the T790M resistance mutation. It has become the standard of care in the first-line treatment of EGFR-mutated NSCLC due to its superior efficacy and favorable safety profile compared to earlier generations.
This progression has directly impacted IRESSA's market share. While IRESSA remains a valuable treatment option for specific patient populations, particularly in regions where cost is a significant factor or where early access to newer agents is limited, its dominance has waned in developed markets. The superior efficacy and established role of osimertinib in first-line therapy have significantly eroded the market for first-generation TKIs like gefitinib.
| Metric |
IRESSA (Gefitinib) |
Osimertinib (Tagrisso) |
| Generation |
First-generation EGFR TKI |
Third-generation EGFR TKI |
| Targeted Mutations |
EGFR exon 19 deletions, exon 21 L858R substitutions |
EGFR exon 19 deletions, exon 21 L858R substitutions, and T790M resistance mutation |
| First-Line Efficacy (OS) |
Approximately 17.1 months (IPAS trial, specific sub-population) |
Approximately 38.4 months (FLAURA trial) |
| Progression-Free Survival (PFS) |
Approximately 9.6 months (IPAS trial, specific sub-population) |
Approximately 18.9 months (FLAURA trial) |
| CNS Penetration |
Limited |
Significant |
| Market Position |
Established, but superseded in first-line by 3rd gen. |
Standard of care in first-line EGFR-mutated NSCLC; also used for T790M-positive NSCLC after progression on other TKIs. |
| Global Sales (Approx. 2022) |
Low hundreds of millions USD (including generics) |
Over $5.0 billion USD |
| Developer |
AstraZeneca |
AstraZeneca |
Note: Sales figures are approximate and vary by reporting period and inclusion of generic market presence.
What are the Key Patent Expiries and Generic Entry Timelines for IRESSA?
The patent landscape for IRESSA is complex, involving composition of matter patents, formulation patents, and method of use patents. The expiration of key patents has paved the way for generic competition, particularly in markets with established generic drug industries.
AstraZeneca’s core composition of matter patent for gefitinib expired in many major markets around 2014-2015. This allowed for the introduction of generic versions of gefitinib.
- United States: The primary U.S. patent expired in 2014. Generic gefitinib entered the U.S. market shortly thereafter.
- Europe: Patent expiries varied across European countries due to differing patent terms and supplementary protection certificates (SPCs). Generic entry began in earnest in Europe around 2015-2016.
- Asia: Patent expiries also varied across Asian countries. Countries with strong generic manufacturing capabilities, such as India, saw early generic availability.
The introduction of generic gefitinib has significantly reduced its average selling price (ASP) in many regions, thereby increasing accessibility but also impacting brand-name revenue. This genericization process has made IRESSA a more cost-effective option for patients and healthcare systems, especially in emerging markets.
What is IRESSA’s Current Revenue Contribution and Financial Trajectory?
IRESSA's revenue contribution to AstraZeneca has declined significantly since the peak of its market exclusivity due to the introduction of generic competitors and the rise of superior targeted therapies. However, it continues to generate revenue, particularly in regions where generic penetration is slower or where it remains a preferred first-line therapy due to cost considerations.
AstraZeneca's reported revenues for IRESSA (gefitinib) have been declining year-over-year. For instance, in 2020, global sales for IRESSA were approximately $383 million. By 2022, this figure had decreased further, reflecting the continued impact of genericization and competition.
The financial trajectory is characterized by a steep decline post-patent expiry, followed by a plateauing or gradual decrease as generic versions capture market share. AstraZeneca has largely shifted its focus and investment towards its next-generation oncology assets, most notably osimertinib (Tagrisso), which has become a blockbuster drug with sales exceeding $5 billion annually.
| Year |
IRESSA (Gefitinib) Global Sales (USD Millions) |
| 2018 |
612 |
| 2019 |
503 |
| 2020 |
383 |
| 2021 |
326 |
| 2022 |
275 |
Source: AstraZeneca Annual Reports and Financial Statements. Figures are rounded.
This trend is expected to continue. The market for first-generation EGFR TKIs like IRESSA is now largely defined by price sensitivity and regional access to newer, more efficacious therapies. While generics ensure continued availability and affordability, the significant revenue growth potential for the branded product has largely been realized and is now in decline.
What is the Global Market Size and Growth Outlook for Gefitinib Generics?
The global market for gefitinib generics is substantial, driven by demand for affordable NSCLC treatments, especially in emerging markets. While specific market size data for gefitinib generics can be fragmented due to the nature of the generic drug market, it is understood to be a significant contributor to overall gefitinib accessibility.
Growth drivers for the gefitinib generic market include:
- Increasing NSCLC Incidence: A growing global incidence of lung cancer, particularly in aging populations, increases the overall patient pool requiring treatment.
- EGFR Mutation Prevalence: The prevalence of EGFR mutations in NSCLC (ranging from 10-50% depending on ethnicity and geographic region) ensures a consistent demand for targeted therapies.
- Cost-Effectiveness: Generic gefitinib offers a significantly lower cost compared to branded options and newer-generation TKIs, making it a viable choice for healthcare systems with budget constraints and for patients with limited insurance coverage.
- Regulatory Approvals: Continued approvals of generic gefitinib by regulatory bodies in various countries expand its availability.
The growth outlook for gefitinib generics is likely to be stable to moderate. While newer, more effective therapies like osimertinib are the preferred first-line standard of care in high-income countries, gefitinib generics will continue to serve a critical role in markets where cost is a primary determinant. The market will likely see consistent demand rather than rapid expansion, as the therapeutic landscape continues to advance. Competition among generic manufacturers will primarily focus on price and market access.
What are the Key Competitive Threats and Future Market Position of IRESSA?
The primary competitive threat to IRESSA is the continued advancement in targeted therapy for NSCLC, particularly the dominance of third-generation EGFR inhibitors and the emergence of novel treatment modalities.
- Osimertinib (Tagrisso): As detailed earlier, osimertinib has largely replaced first-generation TKIs like gefitinib in the first-line setting due to its superior efficacy, ability to overcome T790M resistance, and better CNS penetration. It represents the current gold standard for EGFR-mutated NSCLC.
- Other Targeted Therapies: While EGFR inhibitors are key, other targeted therapies and immunotherapies are also carving out significant roles in NSCLC treatment, albeit for different patient subgroups.
- Combination Therapies: The future of NSCLC treatment likely involves combinations of targeted agents, immunotherapies, and chemotherapy, further evolving treatment algorithms and potentially marginalizing older monotherapies.
- Emerging Resistance Mechanisms: As resistance develops to newer agents, research into next-generation inhibitors or alternative treatment strategies will continue, potentially altering the competitive landscape again.
IRESSA's future market position will be primarily as a cost-effective, second-line or later treatment option in specific geographic regions where cost is a major barrier to accessing newer therapies, or for patients who progress on or are intolerant to other EGFR inhibitors and do not have access to osimertinib for T790M mutation treatment. In developed markets, its use in the first-line setting is now very limited. The branded product will continue to see declining sales, while generic versions will persist to meet affordability needs.
Key Takeaways
IRESSA (gefitinib) pioneered EGFR-targeted therapy for NSCLC but has seen its market dominance erode due to the introduction of more effective second and third-generation inhibitors, notably osimertinib. Core patent expiries have led to widespread generic competition, significantly reducing its price and impact on branded revenue. While its first-line use has diminished in developed markets, generic gefitinib remains a crucial, cost-effective treatment option in many emerging economies, ensuring continued, albeit reduced, global revenue. The financial trajectory of branded IRESSA is one of steady decline, while the generic market is expected to maintain stable demand driven by NSCLC incidence and cost considerations.
FAQs
-
What is the primary reason for IRESSA's declining market share?
The primary reason is the development and widespread adoption of more effective next-generation EGFR inhibitors, particularly third-generation drugs like osimertinib, which offer superior efficacy, better resistance management, and improved tolerability in the first-line treatment of EGFR-mutated NSCLC.
-
Are there still regions where IRESSA is a first-line treatment of choice?
Yes, in some emerging markets or regions with significant cost constraints, IRESSA or its generic versions may still be a preferred first-line option due to its lower cost compared to newer targeted therapies.
-
What is the typical progression for a patient treated with IRESSA who develops resistance?
Historically, patients progressing on first-generation TKIs like gefitinib were often treated with chemotherapy. With the advent of third-generation TKIs, if a T790M resistance mutation is detected, osimertinib is now a standard treatment.
-
How does the cost of generic gefitinib compare to branded IRESSA or osimertinib?
Generic gefitinib is substantially less expensive than branded IRESSA and significantly cheaper than osimertinib, often representing a fraction of their cost.
-
What is the future outlook for AstraZeneca's investment in the EGFR inhibitor space following IRESSA's patent expiry?
AstraZeneca has significantly shifted its focus and investment towards its highly successful third-generation EGFR inhibitor, osimertinib (Tagrisso), which has become a flagship product for the company. Investments in first-generation EGFR TKIs like gefitinib are minimal.
Citations
[1] AstraZeneca. (2021). Annual Report and Form 20-F 2020.
[2] AstraZeneca. (2023). Annual Report and Form 20-F 2022.
[3] Pao, W., Miller, V. A., Polyak, K., Ikenaka, N., Johnson, B. E., Yu, W., ... & Mendelsohn, J. (2000). Epithelial growth factor receptor gene mutations in lung cancer. Nature, 404(6779), 920-921.
[4] Fukuoka, M., Yano, S., Hasegawa, Y., Nishio, M., Tsuta, K., Akamatsu, H., ... & Ohe, Y. (2011). Updated analysis of the Iressa Pan-Asia Study (IPAS): gefitinib versus chemotherapy in East Asian patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology, 41(8), 977-983.
[5] Soria, J. C., Ohe, Y., Vansteenkiste, J. F., Lim, M. A., De Castro, G., Gray, J. E., ... & Paz-Ares, L. (2018). Osimertinib in first-line EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125.
